Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) — Stock Price
Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) is currently trading at $11.82 USD, up 2.52% today. Over the past 52 weeks, shares have ranged between $3.14 and $15.72. This page tracks Kazia Therapeutics Ltd ADR's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Kazia Therapeutics Ltd ADR (KZIA) market capitalisation.
Kazia Therapeutics Ltd ADR (KZIA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Kazia Therapeutics Ltd ADR's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Kazia Therapeutics Ltd ADR Income Statement — Revenue, Profit & Earnings by Year
Kazia Therapeutics Ltd ADR's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $42.00K | $2.31 Million | $555.00 | $10.00K | $15.18 Million |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | $42.00K | $2.31 Million | $555.00 | $10.00K | $15.18 Million |
| Research & Development | $7.33 Million | $17.38 Million | $15.56 Million | $20.17 Million | $14.54 Million |
| SG&A | $8.72 Million | $13.56 Million | $8.58 Million | $5.11 Million | $7.02 Million |
| Total Operating Expenses | $14.26 Million | $30.77 Million | $24.12 Million | $25.41 Million | $21.56 Million |
| Operating Income | $-14.22 Million | $-28.46 Million | $-24.12 Million | $-25.40 Million | $-6.38 Million |
| EBITDA | $-13.28 Million | $-26.59 Million | $-22.28 Million | $-23.52 Million | $-5.11 Million |
| EBIT | $-14.22 Million | $-28.46 Million | $-24.15 Million | $-25.38 Million | $-6.38 Million |
| Interest Expense | — | — | — | $2.09K | $5.10 Million |
| Income Before Tax | $-22.45 Million | $-27.05 Million | $-20.74 Million | $-25.38 Million | $-8.90 Million |
| Income Tax Expense | $-1.75 Million | $-271.00K | $-271.09K | $-368.00K | $-484.00K |
| Net Income | $-20.70 Million | $-26.78 Million | $-20.47 Million | $-25.01 Million | $-8.42 Million |
Kazia Therapeutics Ltd ADR Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Kazia Therapeutics Ltd ADR's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $6.06 Million | $21.59 Million | $28.08 Million | $35.89 Million | $58.09 Million |
| Total Current Assets | $4.93 Million | $6.14 Million | $10.77 Million | $9.45 Million | $29.39 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $90.00K | $133.00K | $105.00K | $51.00K | $76.00K |
| Inventory | — | — | $-3.79 Million | — | $-84.00K |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $14.36 Million | $31.60 Million | $16.03 Million | $17.61 Million | $20.24 Million |
| Total Current Liabilities | $14.05 Million | $25.80 Million | $7.57 Million | $6.73 Million | $8.33 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-3.95 Million | $-1.02 Million | $-3.44 Million | $-5.52 Million | $-27.59 Million |
| Total Stockholder Equity | $-8.30 Million | $-10.02 Million | $12.05 Million | $18.27 Million | $37.85 Million |
| Retained Earnings | $-134.83 Million | $-115.13 Million | $-89.08 Million | $-68.62 Million | $-44.20 Million |
Kazia Therapeutics Ltd ADR Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Kazia Therapeutics Ltd ADR generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-13.28 Million | $-9.58 Million | $-15.16 Million | $-22.76 Million | $-9.11 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-13.28 Million | $-9.58 Million | $-15.16 Million | $-22.76 Million | $-9.11 Million |
| Investing Cash Flow | — | — | — | $-2.37 Million | $-2.36 Million |
| Financing Cash Flow | $15.98 Million | $5.99 Million | $12.97 Million | $3.73 Million | $28.11 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $653.00K | $533.00K | $1.16 Million | $1.68 Million | $637.00K |
| Depreciation | $934.00K | $1.87 Million | $1.87 Million | $1.87 Million | $1.26 Million |
| Change in Cash | $2.69 Million | $-3.58 Million | $-2.12 Million | $-20.23 Million | $18.82 Million |
Kazia Therapeutics Ltd ADR Earnings History — EPS Actual vs. Analyst Estimates
Track Kazia Therapeutics Ltd ADR's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 07, 2025 | -7.64 | -221.00 | +96.54% |
| Jun 10, 2025 | -12.30 | 0.00 | — |
| Nov 15, 2024 | -31.22 | 0.00 | — |
| Jun 30, 2021 | -0.01 | 0.00 | — |
| Mar 31, 2021 | -0.01 | 0.00 | — |
| Dec 31, 2020 | -0.02 | 0.00 | — |
| Sep 30, 2020 | -0.02 | 0.00 | — |
| Jun 30, 2020 | -0.03 | 0.00 | — |